Inside Sterile Manufacturing of Eye Drops: From Water to Sealed Bottle

An eye drop looks like the simplest dosage form in the pharmacy — a small bottle of clear liquid. In manufacturing reality, it is one of the most demanding. Eye drops are sterile preparations applied to one of the body's most vulnerable surfaces, often to eyes already compromised by surgery or disease. A lapse that would be invisible in a tablet can, in an eye drop, seed a corneal infection or an outbreak of endophthalmitis. That is why sterile ophthalmic manufacturing is regulated alongside injectables in India's Schedule M, and why the process below is engineered around one obsession: never letting a viable microorganism reach the product.

Here is how a modern eye drop is actually made, step by step.

Step 1: The Water System — Where Quality Begins

An eye drop is typically more than 95% water, so the water system is the foundation of the entire plant.

• Purified Water (PW) is produced from potable water through pre-treatment, reverse osmosis and deionisation or distillation, then stored in a continuously circulated, sanitisable loop.
• Water for Injection (WFI) — produced by distillation or validated membrane processes — is used for the final formulation stages and for rinsing critical components.
• The loops are kept hot or continuously moving, sanitised on schedule, and monitored daily for conductivity, total organic carbon and microbial counts against pharmacopoeial limits.

A water system that drifts out of control will quietly contaminate every batch made on it, which is why GMP inspectors scrutinise water data first.

Step 2: Weighing and Compounding

Raw materials — the active pharmaceutical ingredient (e.g. moxifloxacin HCl, travoprost, sodium hyaluronate), tonicity adjusters (sodium chloride, mannitol), buffers (borates, phosphates), viscosity agents (HPMC, CMC) and the preservative system — are weighed in a controlled dispensing area with calibrated balances, each entry verified and recorded.

Compounding follows a validated sequence in stainless steel vessels:

1. Most of the batch water is charged into the manufacturing vessel.
2. Ingredients are added in a defined order — solubilisers and buffers first, then the active, then viscosity agents, which often need specific temperature and hydration time.
3. The batch is mixed until fully homogeneous; in-process samples confirm pH, osmolality and assay before release to filtration.

Formulation targets matter clinically: pH and osmolality are tuned close to tears (roughly pH 7.4 and isotonic ~300 mOsm/kg) to minimise stinging and maximise patient comfort and adherence.

Step 3: Sterilising Filtration

Most ophthalmic solutions cannot survive terminal heat sterilisation in their final plastic containers, so sterility is achieved by filtration through a validated 0.22 µm sterilising-grade membrane filter into a sterile holding vessel. Key controls:

• Bioburden limits before filtration — the pre-filtration solution is tested; a sterilising filter is validated to remove microorganisms, not to rescue a dirty process.
• Filter integrity testing — every filter is bubble-point or diffusion tested before and after use. A failed post-use test condemns the batch.
• Defined hold times — the interval between compounding, filtration and filling is validated and never exceeded.

Step 4: The Aseptic Core — Filling and Sealing

The filtered bulk now enters the cleanest space in the factory:

• Filling takes place in a Grade A zone (unidirectional HEPA-filtered airflow over the open product) with a Grade B background, inside rooms fed by a pressure cascade from cleanest to least clean.
• Bottles, caps and nozzles arrive pre-sterilised (by autoclaving, dry heat, gamma or ethylene oxide, depending on material) and enter through validated transfer hatches.
• Operators enter through multi-stage airlock gowning — sterile coveralls, hoods, goggles, double gloves — and are the single largest contamination risk, which is why their aseptic behaviour is trained, observed and periodically requalified.
• Environmental monitoring runs throughout: active air sampling, settle plates, contact plates on surfaces, glove prints on personnel, and continuous particle counting in Grade A. Results are trended against alert and action limits.

Blow-Fill-Seal (BFS): the gold standard for unit doses

For single-dose, preservative-free units, blow-fill-seal technology is widely regarded as best practice. A BFS machine extrudes pharmaceutical-grade plastic into a parison, blows it into the container shape, fills the metered dose and hermetically seals it — in one continuous, enclosed, automated cycle lasting seconds, with virtually no human contact. The result is an aseptically produced, tamper-evident unit dose that eliminates the preservative question entirely.

Step 5: Proving It Works — Media Fills and Validation

An aseptic line is only trusted because it is periodically challenged:

• Media fills (aseptic process simulations) run the full filling process with sterile growth medium under worst-case conditions — longest duration, all interventions, full staffing. Incubated units must show no growth. Under India's revised Schedule M (December 2023), frequency is risk-based and scale reflects real production.
• Validation is a lifecycle, not an event: process design, qualification and continued process verification, plus an Annual Product Quality Review of every batch, deviation and complaint.

Step 6: Quality Control Release Testing

Every batch is released only after QC confirms the full specification, typically:

Only then does QA release the batch with a Certificate of Analysis — the document your distributor or hospital pharmacy receives with each consignment of products like the Moxilux-D peri-operative range.

Step 7: Stability — Proving the Label Claim

The shelf life on the carton is not an estimate; it is generated by stability studies under ICH Q1A protocols — long-term, accelerated and, where relevant, photostability (ICH Q1B) — on the actual product in its actual container. These studies also determine labelled storage conditions ("store below 25°C", "protect from light") and, for multidose bottles, the in-use period after opening.

Records, Retention and the Long Tail of a Batch

A batch does not end at dispatch. Retention samples from every batch are stored for at least a year past expiry so that any market complaint can be investigated against the actual material. Batch manufacturing records, environmental monitoring data and QC results are retained for years and must be retrievable within hours during an inspection. And every market complaint — a cloudy bottle, a leaking cap, an adverse event report — enters a documented investigation with root-cause analysis and corrective action. This complaints-and-recall loop, formalised in the revised Schedule M, is what turns a single failure into systemic learning rather than a repeated one.

Aseptic vs Terminal Sterilisation: The Decision Logic

The choice of sterility strategy is made at formulation design, and it is governed by product physics, not preference:

Regulators state the hierarchy plainly: terminally sterilise wherever feasible. Where it is not — the majority of the eye drop category — the aseptic process must carry the full burden of sterility assurance, which is why environmental control and media fills matter so much more than the final sterility test.

The Human Factor

Every study of cleanroom contamination reaches the same conclusion: people are the dominant particle and microbe source. A compliant ophthalmic plant therefore invests as heavily in behaviour as in hardware — gowning qualification (each operator periodically demonstrates sterile gowning competency via microbial sampling), aseptic technique observation, restrictions on movement and speech over open product, health monitoring and exclusion rules for operators with infections. Automation, closed systems and BFS technology all share one design goal: engineering the human out of the critical zone.

Why This Matters to Buyers

When a purchase committee compares two moxifloxacin bottles at different prices, the visible product is identical. The difference is everything described above — the water system, the filter integrity records, the media fill history, the stability file. That invisible infrastructure is what a WHO-GMP-compliant manufacturer is actually selling, and it is why documentation packs, not brochures, should drive ophthalmic procurement decisions.

Frequently Asked Questions

Why can't eye drops just be sterilised at the end like canned food?

Many can be — terminal sterilisation of the sealed container is actually the preferred method wherever the formulation and packaging tolerate it, because it gives the highest sterility assurance. But heat degrades many ophthalmic actives and deforms common plastic bottles, so aseptic filtration and filling is the practical route for much of the category. BFS unit doses are also aseptically produced by design.

What is the difference between sterile and preservative-free?

Sterility means the product contains no viable microorganisms at the point of manufacture and release. Preservatives are chemicals added to multidose bottles to keep the product safe after opening, when patients repeatedly expose the tip to air and lashes. Preservative-free products — usually unit doses or special multidose valves — remove the preservative but still must be sterile at manufacture.

How do regulators verify that an aseptic line is truly sterile-capable?

Primarily through media fills (aseptic process simulations using growth medium), environmental monitoring trends, filter integrity records and inspection of the documented Contamination Control Strategy — all required under WHO TRS 1044 Annex 2 and India's revised Schedule M.

What role does the bottle itself play in sterility?

A large one. Container-closure integrity testing verifies the sealed pack keeps microbes out for the full shelf life. Nozzle design affects contamination risk during use, tamper-evident bands protect against interference, and BFS unit doses eliminate re-entry altogether.

How long does it take to manufacture one batch of eye drops?

The physical batch — compounding, filtration, filling — may complete within a day or two. But release requires sterility testing (which alone takes about two weeks of incubation), full QC and QA review, so the true cycle from raw materials to released, shippable batch is typically several weeks.

---

This article is a general educational overview of sterile ophthalmic manufacturing principles and published GMP requirements, not a validation protocol or regulatory substitute.

Want to see our quality documentation before you commit? Request samples and batch records or contact the Oculentis team for a complete technical pack.